Associated Papers
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
Aspyre Lung enables robust variant calling in samples that fail next generation sequencing quality control.
Gray ER et al.
Translational Oncology, 2025
Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants.
Silverman I et al.
Frontiers in Molecular Biosciences, 2024
Beyond Structural Bioinformatics for Genomics with Dynamics Characterization of an Expanded KRAS Mutational Landscape.
Ratnasinghe BD et al.
Biorxiv : the Preprint Server for Biology, 2023
Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscape.
Ratnasinghe BD et al.
Computational and Structural Biotechnology Journal, 2023
Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach.
S UK et al.
Journal of Biomolecular Structure & Dynamics, 2022
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K-MAPK1 inhibition.
Janardhan HP et al.
The Journal of Experimental Medicine, 2020
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants.
Han CW et al.
Cancers, 2020
Intrinsic GTPase Activity of K-RAS Monitored by Native Mass Spectrometry.
Moghadamchargari Z et al.
Biochemistry, 2019
Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene.
Zhang Q et al.
Biomed Research International, 2018
Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.
Adamo P et al.
Oncotarget, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.
Fujii T et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.
Sogabe S et al.
Acs Medicinal Chemistry Letters, 2017
The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.
Lu S et al.
Scientific Reports, 2016
Photocontrol of the GTPase activity of the small G protein K-Ras by using an azobenzene derivative.
Iwata S et al.
Biochemistry and Biophysics Reports, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M et al.
Oncotarget, 2015
KRAS and BRAF mutational status in colon cancer from Albanian patients.
Martinetti D et al.
Diagnostic Pathology, 2014
High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT et al.
Archives of Pathology & Laboratory Medicine, 2012
HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
Niihori T et al.
Journal of Human Genetics, 2011
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
Arcila M et al.
The Journal of Molecular Diagnostics : Jmd, 2011
COLD-PCR enhanced melting curve analysis improves diagnostic accuracy for KRAS mutations in colorectal carcinoma.
Pritchard CC et al.
Bmc Clinical Pathology, 2010
A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations.
Kramer D et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology, 2009
Universal DNA microarray method for multiplex detection of low abundance point mutations.
Gerry NP et al.
Journal of Molecular Biology, 1999
Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status.
Hsu J et al.
Clinical Pathology (thousand Oaks, Ventura County, Calif.), 0